The American Society for Hematology congress was dominated by CAR-T therapies – their potential new uses, how to manage safety issues and bring these costly cellular treatments to patients.
NICE has recommended that Janssen’s Darzalex (daratumumab) should be reimbursed on an interim basis by the Cancer Drugs Fund in pre-treated multiple myeloma, after months of wrangling.
Stopping a cancer trial is either a very good, or very bad thing – and luckily for Ipsen the former was the case after a liver cancer trial of its Cabometyx pill was curtailed because of th
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
